^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Cervical Cancer
    Drug:balstilimab (AGEN2034) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

    Excerpt:
    ...Hazard Ratio for Overall Survival (OS) by treatment assignment, stratified by histology, region of the world, ECOG PS in all patients with PD-L1 positive tumors`Overall survival in patients with PD-L1 positive tumors randomized to BAL vs Investigator's Choice chemotherapy`Hazard Ratio for OS by treatment assignment, stratified by histology, region of the world, ECOG PS in all patients`Overall survival in all patients randomized to BAL vs Investigator's Choice chemotherapy...
    Trial ID:
    BRAVA
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Gynecol Oncol
    Title:

    Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

    Published date:
    08/24/2021
    Excerpt:
    In patients with PD-L1-positive tumors the ORR was 20%, however patients with PD-L1-negative tumors also responded to balstilimab (ORR, 7.9%). Balstilimab demonstrated meaningful and durable clinical activity, with manageable safety, in patients with previously-treated, recurrent/metastatic cervical cancer.
    DOI:
    10.1016/j.ygyno.2021.08.018